EU buys additional vaccine doses against monkeypox despite declining cases

The European Commission said it had secured over 10,000 tecovirimat vaccines against monkeypox, despite the declining number of cases in the European Union (EU)

Monkeypox
Test tubes labelled 'Monkeypox virus positive and negative' are seen in this illustration (Reuters)
IANS Brussels
2 min read Last Updated : Sep 27 2022 | 11:28 AM IST

The European Commission said it had secured over 10,000 tecovirimat vaccines against monkeypox, despite the declining number of cases in the European Union (EU).

The Commission on Monday said the emergency procurement adds to the 334,000 vaccines already purchased by the bloc, reports Xinhua news agency.

The purchase was funded by the Health Emergency Preparedness and Response Authority (HERA) to treat patients in the member states with immediate needs.

European Commissioner for Health and Food Safety Stella Kyriakides said that while the declining number of monkeypox cases in the EU is encouraging, it does not mean that the threat has passed, and the EU should continue to focus on preparedness.

Meanwhile, Commissioner for Crisis Management Janez Lenarcic said: "Monkeypox is one of the priority threats identified as part of the rescEU strategic reserves. These batches of monkeypox antivirals will offer an additional level of protection for our citizens.

"The stocks will be available to the Member States on an urgent-needs-basis."

Since the start of the monkeypox outbreak, 19,827 confirmed cases have been reported from 29 EU/EEA countries, in total 47 cases have been reported from three Western Balkan countries and Turkey, according to the European Centre for Disease Prevention and Control.

The five countries that have reported the most cases since the start of the outbreak are: Spain (7,083), France (3,897), Germany (3,570), the Netherlands (1,221) and Portugal (845).

Deaths have been reported from Spain (3), Belgium (1) and the Czech Republic (1).

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :MonkeypoxEuropean UnionEuropeVaccine

First Published: Sep 27 2022 | 11:28 AM IST

Next Story